Teva Pharmaceutical Industries Limited Sponsored ADR
(NYSE: TEVA)

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva�s active pharmaceutical ingredient (API) business provides vertical integration to Teva�s own pharmaceutical production. The Company�s global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States. In February 2014, the Company's subsidiary, Train Merger Sub, Inc, fully acquired NuPathe Inc. In July 2014, it acquired Labrys.

28.410

+0.580 (+2.08%)
Range 27.955 - 28.460   (1.81%)
Open 27.965
Previous Close 27.830
Bid Price 14.070
Bid Volume -
Ask Price 14.080
Ask Volume -
Volume 11,011,760
Value -
Remark
Delayed prices. Updated at 05 Dec 2025 05:00.
Data powered by
View All Events

About Teva Pharmaceutical Inds ADR

Teva Pharmaceutical Industries Ltd (Teva) is an Israel-based pharmaceutical and drug company. It develops, produces and markets generic drugs in all treatment categories. The Company has a pharmaceutical business, whose principal products include Copaxone and Azilect. Teva�s active pharmaceutical ingredient (API) business provides vertical integration to Teva�s own pharmaceutical production. The Company�s global operations are conducted from North and Latin America to Europe and Asia. Teva operates a number of subsidiaries in such countries as Canada, Croatia, the Czech Republic, France, Germany, Hungary, Ireland, Israel, Japan, Poland, the Russian Federation, Spain, the Netherlands, the United Kingdom and the United States. In February 2014, the Company's subsidiary, Train Merger Sub, Inc, fully acquired NuPathe Inc. In July 2014, it acquired Labrys.

Loading Chart...

Please login to view stock data and analysis